Lorlatinib: a new-generation drug for ALK-positive NSCLC

Research output: Contribution to journalComment/debate

5 Scopus citations

Fingerprint

Dive into the research topics of 'Lorlatinib: a new-generation drug for ALK-positive NSCLC'. Together they form a unique fingerprint.